Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report 2025

This Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size has grown exponentially in recent years. It will grow from $2.0 billion in 2024 to $2.6 billion in 2025 at a compound annual growth rate (CAGR) of 30%. The growth observed in the historical period can be linked to the increasing prevalence of non-alcoholic steatohepatitis, modern dietary trends that include high consumption of processed foods, sedentary lifestyles, and the rising occurrence of metabolic conditions.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size is expected to see exponential growth in the next few years. It will grow to $7.38 billion in 2029 at a compound annual growth rate (CAGR) of 29.8%. The anticipated growth during the forecast period is driven by the rising rates of obesity and obesity-related conditions, early interventions, improved reimbursement mechanisms, expanded insurance coverage, and heightened awareness of liver diseases. Key trends expected to shape this period include advancements in technology, the development of new treatments in the pipeline, strategic partnerships and collaborations, personalized medicine, precision therapeutics, and increased investment in clinical trials and research.

The growing prevalence of obesity is expected to drive the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in the future. Obesity is a condition marked by excessive body fat accumulation, which can harm overall health and is usually defined by a body mass index (BMI) of 30 or higher. The global rise in obesity is primarily attributed to factors such as sedentary lifestyles, poor dietary habits, and metabolic risks. MASH treatment in obesity aims to combat insulin resistance, reduce liver fat, and enhance metabolic health through both lifestyle modifications and targeted treatments. For example, a report from the World Heart Foundation, a Switzerland-based global cardiovascular organization, published in March 2023, highlighted that around 2.3 billion adults and children worldwide are obese or overweight, and this figure is expected to increase to 2.7 billion by 2025, reflecting the ongoing obesity trend. Consequently, the rise in obesity rates is propelling the growth of the MASH treatment market.

Major companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focusing on the development of innovative products, including solutions for liver fibrosis. These treatments aim to address the root causes of liver damage, with a focus on lifestyle changes, antiviral medications, and emerging antifibrotic therapies. The goal is to prevent the progression of fibrosis, potentially reversing it, and enhancing liver function. For example, in March 2024, Madrigal Pharmaceuticals, a US-based biopharmaceutical company, received FDA approval for Rezdiffra (resmetirom). This is the first-ever treatment for MASH with moderate to severe liver fibrosis. Rezdiffra, a daily oral tablet, showed effectiveness in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This breakthrough provides a non-invasive alternative to liver biopsies, significantly improving patient access and outcomes in managing fatty liver disease.

In January 2024, Suzhou Ribo Life Science Co., Ltd., a clinical-stage company based in China, and Ribocure Pharmaceuticals AB (Ribo), a clinical-stage biotechnology company from Sweden, announced a $2 billion collaboration with Boehringer Ingelheim. This partnership aims to develop innovative treatments for nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH). The collaboration will combine Ribo’s RNAi therapeutic platform with Boehringer Ingelheim’s expertise in cardiovascular, renal, and metabolic diseases. The goal is to address the critical need for effective therapies that can halt the progression of NASH and restore liver function. Boehringer Ingelheim, a pharmaceutical company based in Germany, is actively working on treatments for MASH.

Major players in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, and Hepion Pharmaceuticals.

North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metabolic dysfunction-associated steatohepatitis (MASH) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Treatment for metabolic dysfunction-associated steatohepatitis (MASH) involves both medical and lifestyle approaches that target the inflammation and liver damage caused by fat buildup in the liver, which is linked to metabolic issues such as obesity, diabetes, and insulin resistance. The goal is to improve liver function and metabolic health outcomes.

The primary treatments for MASH include medications and therapies. Drug treatments involve the use of pharmaceutical agents to reduce liver inflammation, fibrosis, and fat accumulation, aiming to enhance liver function and halt disease progression. These treatments are provided to patients through various channels, including hospital pharmacies, online pharmacies, retail pharmacies, and specialty clinics, and can be used in settings such as hospitals, homecare, and others.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report is one of a series of new reports that provides metabolic dysfunction-associated steatohepatitis (MASH) treatment market statistics, including metabolic dysfunction-associated steatohepatitis (MASH) treatment industry global market size, regional shares, competitors with metabolic dysfunction-associated steatohepatitis (MASH) treatment market share, detailed metabolic dysfunction-associated steatohepatitis (MASH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic dysfunction-associated steatohepatitis (MASH) treatment industry. This metabolic dysfunction-associated steatohepatitis (MASH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolic dysfunction-associated steatohepatitis (MASH) treatment market consists of revenues earned by entities by providing services such as clinical care services, nutritional counseling, pharmacotherapy management, patient education, and support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic dysfunction-associated steatohepatitis (MASH) treatment market also includes sales of antioxidants, antidiabetic drugs, and liver protective supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.